Overview

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Phase:
Phase 2
Details
Lead Sponsor:
BioCryst Pharmaceuticals